The recent acquisitions of Euroscreen Products and Evotec Technologies have strengthened PE's position in the cellular analysis sector as well as showing its commitment to provide more high content screening (HCS) options for its biotechnology customers.
Kevin Lorenc, PerkinElmer vice president of corporate communications, told LabTechnologist.com: "the acquisitions confirm our key growth strategy in advanced cellular sciences, and both are part of building our cellular screening and cellular science business, where we see a very bright future for us with a lot of growth prospects."
The acquisition of Euroscreen Products from Euroscreen SA, adds G protein-coupled receptor (GPCR) membranes, cell lines and the AequoScreen assay platform to its offering.
The AequoScreen luminescent assay platform fits nicely with PE's LumiLux instrument and will allow greater detail and more robust data to be collected for the identification and classification of cellular receptors in the discovery of new therapeutic compounds
The assay platform is based on aequorin technology, based on a naturally occurring photoprotein, and generates large, luminescent signals that result in higher quality data, while reducing the number of false positives in high throughput and ultra-high throughput screening environments.
PE's GPCR portfolio already contains a number of well-respected assay tool and kits including AlphaScreen ERK, LANCE and LANCE Ultra which have broad potential for identifying cellular targets in a wide range of disease states including hypertension, gastrointestinal and neurological disorders.
The acquisition of Evotec Technologies has given PE access to HCS instruments and software that allow efficient and accurate determination of the composition of cells; enabling PE to provide a wider range of custom HCS solutions to drug discovery customers.